Incyte is racing to turn Jakafi’s blockbuster cash engine into a diversified multi-pillar growth platform before the 2028 patent cliff hits.
Overview
Incyte enters 2026–2030 at an inflection point: Jakafi, still ~60% of revenue, faces LOE in 2028, forcing rapid diversification. Financially, 2025 set a record base with $5.14B revenue (+21%) and net product sales $4.35B (+20%), and Q1 2026 sustained momentum with $1.27B revenue (+21%). Management guidance for 2026 net product revenue of $4.77B–$4.94B implies 10%–13% growth, moderated by Opzelura net-price actions to widen access and by the Jakafi XR transition. Strategically, Incyte is building a “multi-pillar” profile: Opzelura grew to $678M in 2025; ex‑Jakafi oncology revenues are scaling quickly; povorcitinib has an HS NDA accepted with a potential 2027 launch; and multiple high-value genomic programs approach pivotal testing. The market remains cautious (Hold consensus) due to the 2028 cliff and dense clinical execution risk.